Royalties ? In January 2016, the Company signed a license agreement with The Royal Institution for the Advancement of Learning/McGill University in Canada on the Company?s potential products. This agreement requires, for each of the Company?s potential products, a 3% payment of annual net revenues, with a minimum royalty of CAD $5,000 each, per year starting on the date of commercialization of the first product developed using the intellectual property covered by the license agreement. The Company must pay milestone payments for the testosterone replacement therapy as follows:  CAD $5,000 on the issuance of the first US patent  CAD $25,000 on the filing of an investigational new drug application or regulatory filing  CAD $50,000 on the initiation of the first Phase II clinical study  CAD $100,000 on the initiation of the first Phase III clinical study  CAD $300,000 on receipt of regulatory approval The Company must also pay milestone payments as follows for the out of body test to identify Alzheimer?s disease as follows:  CAD $5,000 on the issuance of the first US patent  CAD $50,000 on the filing of a 510(k) or PMA application  CAD $200,000 on receipt of regulatory approval In addition, the Company issued 5% of the total number of issued and outstanding shares in the Company?s Series A financing to the same institution, or 1,652,632 shares in March 2016. This agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company?s common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Company?s outstanding common stock, it is considered a related party. Research Agreement ? In January 2016 the Company signed a Research Agreement with The Royal Institution for the Advancement of Learning/McGill University in Canada for research activities on the Company?s potential products. The agreement covers a period of one year and requires the C